| Background and ObjectiveCoronary heart disease (CHD) is a common organ pathological change due to atherosclerosis (AS). For half a century, CHD has become one of the most serious diseases that has become a threat to human health all over the world. Acute coronary syndrome (ACS) is a novel concept proposed in recent years about a series of diseases of acute myocardial ischaemia, including unstable angina pectoris (UAP), non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). All patients with ACS may account for more than 50% of that with CHD. In contrast to stable CHD, ACS has always showed to be of sudden onset and sharp progressed . There is higher risk of sudden death and worse prognosis in these patients with ACS since often lacking necessary medical protection. So, ACS has received widespread attention in the recent years. Early assessment of the risk of ACS and early intervention to reduce it's mortality and morbidity, has become a major challenge that the medical profession needs to face in the 21st century. Adiponectin is a novel, adipose-specific secretary protein in the blood which was discovered in 1995. Since its discovery, many studies have indicated that adiponectin is a collagen-like plasma protein produced specifically by white adipose tissue and is abundantly present in the plasma. Adiponectin has close correlation with obesity, diabetes mellitus, insulin resistance and CHD. Previous studies have shown that adiponectin does not only have the effect of anti-atherosclerosis, but also has relation with the rupture of atherosclerotic plaque. This study is aimed to investigate the relationship between the plasma level of adiponectin and ACS by measuring the plasma adiponectin levels in the patients with ACS.Methods92 patients with CHD were divided into two groups according to the coronary angiography and clinical manifestation: ACS group (n=72), and stable angina pectoris (SAP) group (n=20). Moreover, the ACS group was divided into three subgroups: ST elevation myocardial infarction (STEMI) group (n=33), non-ST elevation myocardial infarction (NSTEMI) group (n=15), and unstable angina pectoris (UAP) group (n= 24). 18 patients with normal coronary angiography were in the control group. Plasma levels of adiponectin were measured in all the patients by enzyme-linked immunosorbent assay (ELISA), and interrelated data such as body mass index (BMI), lipids, and smoking history were also collected at the same time.Results(1)Plasma levels of adiponectin in the patients with ACS was significantly lower than that in patients with SAP and in the control group[(7.5±3.2vs 11.7±4.1/12.0±4.8)mg/L, P <0.05 ) ], but there were no significant difference between SAP and the control group[(11.7±4.1vs 12.0±4.8)mg/L, P >0.05]. (2)Plasma levels of adiponectin in the three subgroups of ACS were lower than SAP group and the control group[(7.2±3.5 vs 11.7±4.1/12.0±4.8)mg/L, (7.5±3.1 vs 11.7±4.1/ 12.0±4.8) mg/L, (8.0±3.2 vs 11.7±4.1/12.0±4.8)mg/L, P<0.05]. However, no sig- nificant differences were found between these three subgroups[(7.2±3.5 vs 7.5±3.1 vs 8.0±3.2)mg/L, P>0.05]. (3)Plasma levels of adiponectin correlated negatively with BMI (r = - 0.23, P< 0.05), and correlated positively with high density lipoprotein cholesterol (HDL-C) levels (r = 0.32, P<0.05). Plasma levels of adiponectin in the male group with smoking history was lower than that with no smoking history [(8.3±3.4 vs 13.0±4.3)mg/L, P<0.05]. ConclusionsAdiponectin, being a rare adipose-specific protein having effect in anti-atherosclerosis, has close correlation with ACS. Plasma level of adiponectin can be used as an index for predicting ACS. |
PDF Full Text Request